Number of the records: 1

Advances in Chemical Biology

SYSNO ASEP	0502886
Document Type	M - Monograph Chapter
R&D Document Type	Monograph Chapter
Title	PPM1D as a driver and pharmacological target in clonal hematopoiesis
Author(s)	Macůrek, Libor (UMG-J)_{RID, ORCID}
Source Title	Advances in Chemical Biology. - Praha : OPTIO CZ, 2019 / Bartůněk Petr - ISBN 978-80-88011-03-3
Pages	s. 32-39
Number of pages	7 s.
Number of copy	50
Number of pages	210
Publication form	Print - P
Language	eng - English
Country	CZ - Czech Republic
Keywords	cancer ; phosphatase ; DNA damage response ; inhibitor ; clonal hematopoiesis
Subject RIV	EB - Genetics ; Molecular Biology
OECD category	Cell biology
R&D Projects	LO1220 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
Institutional support	UMG-J - RVO:68378050
Annotation	Chemotherapy or radiotherapy cause genotoxic stress that kills cancer cells and ideally only tolerable DNA damage to the neighboring healthy tissues. Cell fate after exposure to genotoxic stress is determined by the tumor suppressor p53 that controls transcription of both pro-survival and pro-apoptotic genes. Depending on the DNA damage load, cells activate the cell cycle checkpoint arrest or die through programmed cell death. Protein phosphatase 2C delta (referred to as WIP1) is a negative regulator of p53 and has been proposed as potential pharmaceutical target. Recently, mutations in PPM1D were observed in patients that developed secondary cancer after receiving a chemotherapy. This review will discuss the role of PPM1D in development of the secondary cancers as well as potential use of small-molecule inhibitors as prevention to causing these adverse effects of chemotherapy.
Workplace	Institute of Molecular Genetics
Contact	Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217
Year of Publishing	2019

Number of the records: 1